Program
Fluorouracil
Also written as “5-Fluorouracil”, “fluorouracil” and “5-fluorouracil”.
Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Neoplasms · Head and Neck Neoplasms · Stomach Neoplasms, led by 12 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 160 open or running | phase 4since Sep 14, 2006 | Jan 6, 2001 | none ahead |
| Pfizer | 51 open or running | phase 3since Jan 28, 2000 | Jan 28, 2000 | none ahead |
| Jiangsu HengRui Medicine | 21 open or running | phase 3since Feb 20, 2023 | Mar 8, 2021 | none ahead |
| Otsuka | 20 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| prologue-research-international | 20 open or running | phase 3since Jun 5, 2003 | May 6, 2001 | none ahead |
| Almirall | 10 open or running | phase 3since Nov 10, 2014 | Nov 10, 2014 | none ahead |
| cbsbioscience | 10 open or running | phase 2since Nov 10, 2016 | Nov 10, 2016 | none ahead |
| encube-ethicals-pvt-ltd | 10 open or running | phase 3since Sep 23, 2021 | Sep 23, 2021 | none ahead |
| healthcare-global-enterprise-ltd | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 3since Feb 25, 2019 | Feb 25, 2019 | none ahead |
| sol-gel-technologies-ltd | 10 open or running | phase 3since Oct 30, 2018 | Oct 30, 2018 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Nov 25, 2015 | Nov 25, 2015 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, parexel, Halozyme Therapeutics, biolinerx-ltd, baili-bio-chengdu-pharmaceutical-co-ltd, quintiles-inc, Takeda, almirall-hermal-gmbh and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Jan 28, 2000.
- Jan 28, 20083 phase 2 studiesSanofi · NCT00612495, NCT00611754, NCT00611507
- Oct 28, 2008Phase 2 study in Uterine NeoplasmsSanofi · NCT00782041 · 11 enrolled · Thailand
- Sep 22, 2009Phase 3 study in Head and Neck NeoplasmsSanofi · NCT00995293 · 240 enrolled · China
- Aug 14, 2013Phase 1 study in NeoplasmsSanofi · NCT01930552 · 20 enrolled · China
- Nov 10, 2014Almirall's first study: phase 3 study in Keratosis, ActinicNew to AlmirallAlmirall · NCT02289768 · 166 enrolled · Germany, United Kingdom
- Nov 25, 2015Teva Pharmaceutical Industries's first study: phase 3 study in Keratosis, ActinicNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02616601 · 422 enrolled · United States
- Sep 29, 2016healthcare-global-enterprise-ltd's first study: phase 2 study in Tongue NeoplasmsNew to healthcare-global-enterprise-ltdhealthcare-global-enterprise-ltd · NCT02985255 · 30 enrolled · India
- Nov 10, 2016cbsbioscience's first study: phase 2 study in Hepatocellular Carcinoma Non-ResectableNew to cbsbiosciencecbsbioscience · NCT02967887 · 96 enrolled · Korea, Republic of
- Oct 30, 2018sol-gel-technologies-ltd's first study: phase 3 study in Keratosis, ActinicNew to sol-gel-technologies-ltdsol-gel-technologies-ltd · NCT03727074 · 462 enrolled · United States
- Feb 25, 2019Sino Biopharmaceutical's first study: phase 3 study in Squamous Cell Carcinoma of Head and NeckNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03855384 · 334 enrolled · China
- Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
- Mar 8, 2021Jiangsu HengRui Medicine's first study: phase 1 study in Advanced Pancreatic CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04796948 · 41 enrolled · China
- Sep 23, 2021encube-ethicals-pvt-ltd's first study: phase 3 study in Keratosis, ActinicNew to encube-ethicals-pvt-ltdencube-ethicals-pvt-ltd · NCT05078827 · 458 enrolled · United States
- Feb 20, 2023Phase 3 study in First-line Treatment of Advanced Pancreatic CancerJiangsu HengRui Medicine · NCT05751850 · 778 planned · China
TargetBeta
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Capecitabinerule | Hoffmann-La Roche | phase 4 | 129 |
| Tegafurrule | Otsuka | phase 3 | 25 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05751850First-line Treatment of Advanced Pancreatic Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2024 | 778 |
| NCT05078827Keratosis, Actinic · United States | 3 | Completed | encube-ethicals-pvt-ltd | Nov 1, 2022 | 458 |
| NCT04796948Advanced Pancreatic Cancer · China | 1 | Completed | Jiangsu HengRui Medicine | Jun 28, 2024 | 41 |
| NCT04607421Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 1, 2025 | 841 |
| NCT03855384Squamous Cell Carcinoma of Head and Neck · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2020 | 334 |
| NCT03727074Keratosis, Actinic · United States | 3 | Completed | sol-gel-technologies-ltd | Dec 19, 2019 | 462 |
| NCT02967887Hepatocellular Carcinoma Non-Resectable · Korea, Republic of | 2 | UNKNOWN | cbsbioscience | Oct 2018 | 96 |
| NCT02985255Tongue Neoplasms · India | 2 | UNKNOWN | healthcare-global-enterprise-ltd | Jun 2017 | 30 |
| NCT02616601Keratosis, Actinic · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 17, 2015 | 422 |
| NCT02289768Keratosis, Actinic · Germany, United Kingdom | 3 | Completed | Almirall | Sep 2015 | 166 |
| NCT01930552Neoplasms · China | 1 | Completed | Sanofi | Dec 2014 | 20 |
| NCT00995293Head and Neck Neoplasms · China | 3 | Completed | Sanofi | Jan 26, 2018 | 240 |
| NCT00782041Uterine Neoplasms · Thailand | 2 | Terminated | Sanofi | Aug 2003 | 11 |
| NCT00612495Endometrial Neoplasms · France | 2 | Completed | Sanofi | 31 | |
| NCT00611754Head and Neck Neoplasms · France | 2 | Completed | Sanofi | 15 | |
| NCT00611507Stomach Neoplasms · Colombia | 2 | Completed | Sanofi | 21 | |
| NCT00559455Carcinoma, Hepatocellular · Korea, Republic of | 2 | Completed | Sanofi | Jan 2010 | 38 |
| NCT00555672Stomach Neoplasms · Spain | 1 | Completed | Pfizer | Dec 2009 | 34 |
| NCT00499850Adenocarcinoma · Australia | 1 | Completed | Sanofi | Jun 2006 | 18 |
| NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more | 3 | Completed | Sanofi | Mar 2010 | 371 |
| NCT00401323Head and Neck Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Jun 2003 | 568 |
| NCT00382720Stomach Neoplasms · United States, Belgium, France and more | 2 | Completed | Sanofi | Apr 2010 | 275 |
| NCT00377273Keratosis, Actinic · United States | 4 | Completed | Sanofi | 250 | |
| NCT00343239Stomach Neoplasms · Turkey | 2 | Completed | Sanofi | Mar 2012 | 59 |
| NCT00261703Head and Neck Neoplasms · Portugal, Spain | 3 | Completed | Sanofi | Jul 2010 | 439 |
| NCT00259402Esophageal Neoplasms · Spain | 2 | Completed | Sanofi | Oct 2008 | 41 |
| NCT00143403Colorectal Neoplasms · Belgium, Denmark, France and more | 3 | Completed | Pfizer | Feb 2008 | 321 |
| NCT00400179Stomach Neoplasms · United States, Canada | 3 | Completed | Otsuka | Mar 2008 | 1,053 |
| NCT00062426Colorectal Neoplasms · United States | 3 | Completed | prologue-research-international | ||
| NCT00026273Colorectal Neoplasms · Austria, Belgium, Egypt and more | 3 | Completed | Pfizer | Sep 2004 | |
| NCT00016198Colorectal Neoplasms · United States | 2 | Completed | prologue-research-international | Apr 2003 | |
| NCT00008281Colorectal Neoplasms · United States, Canada | 3 | UNKNOWN | Sanofi | ||
| NCT00005871Pancreatic Neoplasms · United States | 3 | UNKNOWN | Otsuka | ||
| NCT00004252Colorectal Neoplasms · United States | 3 | Completed | Pfizer | Sep 2007 |
How it is read
Names in the registry
- “5-Fluorouracil”, 10 entries
- “fluorouracil”, 9 entries
- “Fluorouracil”, 8 entries
- “5-fluorouracil”, 7 entries
- “5-FU”, 5 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 18 studies
- Pancreatic Neoplasms, 9 studies
- Neoplasms, 7 studies
- Head and Neck Neoplasms, 7 studies
- Stomach Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.